Literature DB >> 2488107

Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents.

P J Silver1, M J Connell, K M Dillon, W R Cumiskey, W A Volberg, A M Ezrin.   

Abstract

Class III antiarrhythmic agents may prolong refractoriness via modulation of ion channels, which may be sensitive to Ca2+ regulatory proteins or enzymes. Accordingly, the purpose of this study was to quantitate the effects of several structurally diverse class III antiarrhythmic agents on calmodulin-regulated enzymes and protein kinase C activity, and to evaluate the ability of these agents and known calmodulin antagonists to prolong cardiac refractoriness in vivo. The rank order of potency (IC50;microM) of selected class III antiarrhythmic agents and reference calmodulin antagonists as inhibitors of calmodulin-regulated phosphodiesterase activity were: calmidazolium (0.12 microM) greater than amiodarone (0.62 microM) greater than desethylamiodarone (1.5 microM) greater than trifluoperazine (4.3 microM), bepridil (5 microM) greater than W-7 (7.5 microM), clofilium (13 microM). Similar concentration-related inhibition was evident in a second calmodulin-regulated system, inhibition of myosin light-chain phosphorylation and superprecipitation of arterial actomyosin. Sotalol and tetraethylammonium were inactive at 100 microM. Protein kinase C activity was also inhibited by some of these agents; desethylamiodarone (IC50 = 11 microM) was more potent than the reference agent, H-7 (IC50 = 79 microM), or amiodarone (38% inhibition at 100 microM) and clofilium (32% inhibition at 100 microM). In vivo, the minimally effective doses required to increase ventricular effective refractory periods in paced guinea pigs were (in mg/kg) bepridil, sotalol [1] greater than clofilium [3] greater than amiodarone [10] greater than W-7, desethylamiodarone [20]. No changes in refractory period were noted with maximum testable doses of calmidazolium or trifluoperazine. These studies show that some, but not all, class III antiarrhythmic agents are effective and potent calmodulin antagonists or protein kinase C inhibitors. Moreover, some calmodulin antagonists are effective at prolonging refractoriness in vivo. However, a lack of correlation between these agents suggests that these mechanisms are not solely responsible for the prolongation of refractoriness of all class III agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2488107     DOI: 10.1007/bf01857619

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  22 in total

1.  Phosphorylation of ion channels.

Authors:  I B Levitan
Journal:  J Membr Biol       Date:  1985       Impact factor: 1.843

Review 2.  Protein kinase C in the regulation of smooth muscle contraction.

Authors:  H Rasmussen; Y Takuwa; S Park
Journal:  FASEB J       Date:  1987-09       Impact factor: 5.191

3.  Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

Authors:  R E Weishaar; S D Burrows; D C Kobylarz; M M Quade; D B Evans
Journal:  Biochem Pharmacol       Date:  1986-03-01       Impact factor: 5.858

4.  Inhibition of calcium-activated potassium conductance of human erythrocytes by calmodulin inhibitory drugs.

Authors:  I Lackington; F Orrego
Journal:  FEBS Lett       Date:  1981-10-12       Impact factor: 4.124

5.  Effects of calcium antagonists and vasodilators on arterial myosin phosphorylation and actin-myosin interactions.

Authors:  P J Silver; J Dachiw; J M Ambrose
Journal:  J Pharmacol Exp Ther       Date:  1984-07       Impact factor: 4.030

6.  Effects of the calmodulin inhibitor, trifluoperazine, on membrane potentials and slow action potentials of cultured heart cells.

Authors:  G Bkaily; N Sperelakis; M Eldefrawi
Journal:  Eur J Pharmacol       Date:  1984-10-01       Impact factor: 4.432

7.  Effects of metal cations and calmodulin antagonists on [3H] nitrendipine binding in smooth and cardiac muscle.

Authors:  E M Luchowski; F Yousif; D J Triggle; S C Maurer; J G Sarmiento; R A Janis
Journal:  J Pharmacol Exp Ther       Date:  1984-09       Impact factor: 4.030

8.  Delayed rectification in the cardiac Purkinje fiber is not activated by intracellular calcium.

Authors:  R S Kass
Journal:  Biophys J       Date:  1984-04       Impact factor: 4.033

9.  Comparative antiarrhythmic and electrophysiological effects of drugs known to inhibit calmodulin (TFP, W7 and bepridil).

Authors:  E Barron; R J Marshall; M Martorana; E Winslow
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

10.  Two types of calcium-dependent protein phosphorylations modulated by calmodulin antagonists. Naphthalenesulfonamide derivatives.

Authors:  T Tanaka; T Ohmura; T Yamakado; H Hidaka
Journal:  Mol Pharmacol       Date:  1982-09       Impact factor: 4.436

View more
  4 in total

1.  Amiodarone-associated Optic Neuropathy-A Clinical Criteria-based Diagnosis?

Authors:  Katrin Fasler; Ghislaine L Traber; Gregor Peter Jaggi; Klara Landau
Journal:  Neuroophthalmology       Date:  2017-08-18

2.  The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.

Authors:  Jakob Gierten; Eckhard Ficker; Ramona Bloehs; Patrick A Schweizer; Edgar Zitron; Eberhard Scholz; Christoph Karle; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-24       Impact factor: 3.000

3.  Antiarrhythmic drugs, clofilium and cibenzoline are potent inhibitors of glibenclamide-sensitive K+ currents in Xenopus oocytes.

Authors:  H Sakuta; K Okamoto; Y Watanabe
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

Review 4.  Putative therapeutic applications of calmodulin antagonists.

Authors:  R Mannhold; H Timmerman
Journal:  Pharm Weekbl Sci       Date:  1992-08-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.